Vibrenta Injection 100 IU/ml contains Insulin Glargine, a long-acting recombinant human insulin analogue used for the management of diabetes mellitus. It is designed to provide a steady, basal level of insulin over an extended period, helping to maintain consistent blood glucose control throughout the day and night. Vibrenta Injection is suitable for both adult and pediatric patients who require basal insulin therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Long-acting insulin analogue
Antidiabetic agent

Pharmacology

Insulin Glargine is a modified form of human insulin produced using recombinant DNA technology. Structural changes in the insulin molecule allow it to be less soluble at physiological pH. After subcutaneous injection, insulin glargine forms microprecipitates in the subcutaneous tissue, from which small amounts of insulin are slowly and continuously released into the bloodstream. This results in a prolonged, peakless insulin action lasting up to 24 hours.

Insulin glargine binds to insulin receptors on target tissues such as liver, muscle, and adipose tissue, facilitating glucose uptake and utilization while inhibiting hepatic glucose production. These actions help reduce both fasting and basal blood glucose levels with a lower risk of fluctuations.

Indications

Vibrenta Injection 100 IU/ml is indicated for:

• Treatment of diabetes mellitus in adults, adolescents, and children who require basal insulin

• Type 1 diabetes mellitus, as part of a basal-bolus insulin regimen

• Type 2 diabetes mellitus when blood glucose control is inadequate with oral antidiabetic agents or other insulin therapies

Dosage and Administration

The dosage of Vibrenta Injection should be individualized based on the patient’s metabolic needs, blood glucose monitoring results, and clinical response.

Insulin glargine is administered once daily by subcutaneous injection, preferably at the same time each day. Common injection sites include the abdomen, thigh, or upper arm. Injection sites should be rotated within the same anatomical region to reduce the risk of lipodystrophy.

Vibrenta Injection must not be administered intravenously or mixed with other insulins, as this may alter its pharmacokinetic profile.

Contraindications

Vibrenta Injection is contraindicated in patients with:

• Hypoglycemia

• Known hypersensitivity to insulin glargine or any component of the formulation

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

The most common adverse effect of insulin therapy is hypoglycemia, which may occur if the insulin dose is too high relative to food intake or physical activity. Other possible side effects include:

• Injection site reactions such as redness, swelling, or itching

• Lipodystrophy at injection sites

• Weight gain

• Allergic reactions, which are rare but may be severe

Patients should be educated to recognize and manage symptoms of hypoglycemia.

Pregnancy and Lactation

Insulin glargine may be used during pregnancy if clinically required, as maintaining optimal glycemic control is essential for maternal and fetal health. Insulin requirements may change during pregnancy and postpartum periods. Insulin is considered safe during breastfeeding, as it does not pass into breast milk in clinically significant amounts.

Precautions and Warnings

Careful blood glucose monitoring is required during initiation and dose adjustment. Dose modifications may be necessary during changes in diet, physical activity, illness, or stress. Caution is advised when switching from other insulin products to insulin glargine to avoid hypoglycemia or hyperglycemia.

Storage

Store unopened vials in a refrigerator at 2°C–8°C. Do not freeze. Once opened, the vial may be stored below 30°C and used within the recommended period. Protect from direct heat and light. Keep out of reach of children.